Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Table 1 Characteristics of the gastric cancer patient tumour samples analyzed for drug sensitivity

Sex	Age at tumour sampling	Stage at tumour sampling*	Histology	Prior chemotherapy
Male	39	Metastatic	Signet-ring cell	Yes
Female	58	Metastatic	Signet-ring cell	Yes
Male	60	Metastatic	Intestinal	Yes
Male	58	Localized	Diffuse	Yes
Female	71	Localized	Diffuse	Yes
Female	54	Metastatic	Signet-ring cell	Yes
Male	66	Localized	Intestinal	No
Male	75	Localized	Intestinal	Yes
Female	67	Metastatic	Diffuse	Yes
Male	74	Localized	Intestinal	Yes
Female	70	Localized	Intestinal	No
Male	70	Localized	Intestinal	Yes
Male	70	Localized	Intestinal	Yes
Female	61	Localized	Intestinal	No
Female	88	Localized	Intestinal	No
Male	74	Localized	Intestinal	Yes

*Patients with localized disease underwent curative surgery and tumour sampling was from the primary tumour. Patients with metastatic disease had carcinosis, were planned for cytoreductive surgery and intraperitoneal chemotherapy and tumour sampling was from carcinosis.

ISSN: 1756-9966